



## Molecular Studies on *Escherichia coli* Isolated from Diarrheic Dog

\*Aisha R. Ali<sup>1</sup>, Mona A .El Shehedi<sup>1,3</sup>, Mostafa M. Eraqi<sup>2,3</sup>

<sup>1</sup>. Serology Unit and Bacterial Strain Bank, Animal Health Research Institute, Dokki, Egypt.

<sup>2</sup>. Microbiology and Immunology department, Veterinary Research Division, National Research Center, Giza, Egypt.

<sup>3</sup>. Biology department, College of Science, Majmaah University, Kingdom of Saudi Arabia.

\*Corresponding author's E-mail: [azo1974@gmail.com](mailto:azo1974@gmail.com)

Received: 23-03-2018; Revised: 18-04-2018; Accepted: 03-05-2018.

### ABSTRACT

The objective of the present study was the isolation and identification of *E.coli* strains from dogs, serological identification and the detection of the virulence gene characteristics of STEC and attaching-effacing (AE) *eaeA* strains and multidrug resistant gene (MDR). A total of 120 rectal swabs were examined bacteriologically for isolation of *Escherichia coli* from diarrheic dogs in Cairo and Giza governorates from private clinic and veterinary hospitals. Sixty eight isolates of *E. coli* were recovered in percentage of (56.6%), Serogrouping of (68) isolates of *E.coli* revealed "7" different "O" serogroups which were O<sub>157</sub>, O<sub>1</sub>, O<sub>44</sub>, O<sub>128</sub>, O<sub>26</sub>, O<sub>146</sub> and O<sub>55</sub> and (20 strains) were untyped. Antibiogram pattern revealed that the most strains of *E.coli* were resistant to Oxytetracyclin, Ampicillin, Sulphamethazol, Cephalothin and Imipenem, while variable results were recorded with the remaining tested chemotherapeutic agents. Molecular Detection of Extended spectrum  $\beta$ -Lactamase (ESBL) gene and some virulence gene including *stx1*, *stx2* and *eaeA* gene were applied *E.coli* producing *sul1* are under serogroups O<sub>157</sub>, O<sub>1</sub>, O<sub>44</sub>, O<sub>128</sub> and O<sub>26</sub> at 433bp. Also serogroups O<sub>55</sub>, O<sub>146</sub>, O<sub>26</sub>, and O<sub>44</sub> were producing tet (A) at 576 bp. While serogroups O<sub>1</sub>, O<sub>128</sub>, O<sub>26</sub> and O<sub>146</sub> were producing blaTEM gene at 516 bp. Mean while serogroups O<sub>44</sub> and O<sub>128</sub> producing bla CTX at 503 bp. The presence of *eaeA* gene among serogroups O<sub>44</sub> and O<sub>55</sub> were detected at rang 248bp.while *E.coli* isolates examined by PCR showed the presence *stx2* gene among serogroup O<sub>55</sub> only. None of tested serogroups were produced *stx1* .

**Keywords:** *Escherichia coli*, ESBL, *Stx1*, *Stx2*, *eaeA* gene, diarrhea.

### INTRODUCTION

Diarrhea remains one of the main sources of morbidity and mortality in today's world and a large proportion is caused by diarrheagenic strains in human and animals <sup>1</sup>. *Escherichia coli* are a normal commensal bacterial flora of most animals, including dogs and humans. *E.coli* can also cause a wide variety of intestinal and extra-intestinal diseases, such as diarrhea, urinary tract infections, septicaemia and neonatal meningitis <sup>2</sup>, antimicrobial resistance in *E. coli* isolated from pet dogs can be considered a potential threat of infection for the human population. The commensal *E.coli* strains rarely cause disease where the normal gastrointestinal barriers are breached <sup>3</sup>.

Pet dogs were shown to be a potential house hold source of multidrug resistant *E.coli* strains; they detected the simultaneous presence of multidrug-resistant *E.coli* in dogs and their owners, with different phenotypic profiles of antibiotic resistance, especially for ESBL. Furthermore, some strains from dogs and humans of the same household had similar resistance patterns, ESBL genes, identical phylogenetic groups and identical or closely related PFGE profiles. These data demonstrate high degrees of homology and therefore the possibility that resistant *E.coli* clones are circulating between individuals and animals in the same environment. Indeed some strains showed clonal relationships indicating within-household sharing <sup>4</sup>. Suggested that the prevalence of

antimicrobial-resistant commensal *E.coli* is very similar in dogs and humans and there is no difference among the resistant *E.coli* isolated from dog owners and humans without pet dogs. ESBL are the major groups of enzymes that confer resistance to  $\beta$ -Lactamase antibiotic through hydrolyze the  $\beta$ -Lactamase ring in antibiotic.

The increasing prevalence of antimicrobial resistant *E.coli* isolates is a serious concern, particularly with respect to strains producing extended spectrum  $\beta$ -lactamases (ESBLs), both in humans and in animals <sup>5</sup>. ESBL-producing *E.coli* isolates from companion animals are of public health concern, due to potential transfer between animals and humans in the household environment <sup>6</sup>.

The CTX-M-15  $\beta$ -lactamase is an ESBL that has been disseminated among humans in hospitals, mainly associated with *E.coli* strain ST131-B2, although is less frequent in animals<sup>7,8</sup>. Plasmid-mediated AmpC  $\beta$ -lactamase (pAmpC)-producing *E.coli* strains are also an emerging problem in human and veterinary medicine because of the transferability of the resistance genes, that of blaCMY-2 being reported most frequently <sup>9</sup>. ESBL and pAmpC *E.coli* producers have been detected both in healthy and in sick dogs in different countries <sup>10,11,12</sup>. Nevertheless, no information do exist in healthy pets in Latin America <sup>4</sup> investigated the presence of cefotaxime-resistant (CTXR) *E.coli* strains in fecal samples of healthy dogs in Mexico, to characterize the mechanisms of



resistance and to perform molecular typing of selected isolates.

Antimicrobial resistance in *Enterobacteriaceae* poses a critical public health threat, especially in the developing countries<sup>13</sup>, much of the problem has been shown to be due to the presence of transferable plasmids encoding multidrug resistance and their dissemination among different enterobacterial species<sup>14</sup>

Shiga toxin-producing *E.coli* (STEC) is among the most important causes of foodborne diseases. They are responsible for a range of human gastrointestinal diseases, including watery or bloody diarrhea. The common feature and main virulence factor of STEC is the production of Shiga toxin-1 (*stx-1*) and/or Shiga toxin-2 (*stx-2*) or its variants<sup>16</sup>, they also added dogs and cats have also been found to carry STEC strains, but their role as bacterial reservoirs has not been completely elucidated. The prevalence of STEC strains among intestinal bacterial strains in pets has been shown to be of highly variable occurrence. The *E.coli* gene *eaeA* express intimin, which is required for the production of attaching and effacing (AE) lesions in epithelial cells<sup>17</sup>.

## MATERIALS AND METHODS

### Samples and cultivation

A total of 120 rectal swabs were aseptically taken from diarrheic dogs in Cairo and Giza governorates from private clinic and veterinary hospitals. All rectal swabs were inoculated directly into MacConkey's agar and diluted on buffer peptone and sub cultured on EMB agar. The inoculated plates were incubated at 37°C for 24-48 hours. The isolation, purification and biochemical identification of the bacterial isolates were carried out as per standard protocols<sup>18</sup>.

### Serological identification

Antisera *Escherichia coli* were used for serological identification of somatic "O" sera using slide agglutination test (polyvalent sera, 8 vials monovalent sera, 43 vials). All were obtained from DENKA SEIKEN CO. LTD Tokyo, Japan. For somatic antigen was used and interpreted<sup>19</sup>.

### Antibiogram pattern

Antibiotic susceptibility tests were performed by disc diffusion method (Clinical laboratory standard institute, CLSI)<sup>20</sup>, to different "O" serogroups of *E.coli* recovered from diarrheic dogs. The following antibiotics were used Cephalothin, Oxytetracyclin, Sulphamethazol, Cefpodoxime, Ampicillin, Cefotaxime, Ceftazidime, Imipenem, Ceftriaxone and Cefepime (Oxoid) for susceptibility testing. Zones of inhibition were measured after 24-hour incubation at 37°C. Interpretation of sensitivity and resistance was based on EUCAST guidelines<sup>21</sup>.

## Molecular characterization of *E.coli*

PCR assay was carried out in Reference Laboratory for Veterinary Quality Control on Poultry Production as follows:

### DNA extraction

DNA extraction from isolates was performed using the QIAamp DNA Mini kit (Qiagen, Germany, GmbH) with modifications from the manufacturer's recommendations. Briefly, 200 µl of the sample suspension was incubated with 10 µl of proteinase K and 200 µl of lysis buffer at 56°C for 10 min. After incubation, 200 µl of 100% ethanol was added to the lysate. The sample was then washed and centrifuged following the manufacturer's recommendations. Nucleic acid was eluted with 100 µl of elution buffer provided in the kit.

- **Oligonucleotide Primer.** Primers used were supplied from Metabion (Germany) are listed in **table (1)**.
- **PCR amplification.** For uniplex PCR, primers were utilized in a 25µl reaction containing 12.5 µl of EmeraldAmp Max PCR Master Mix (**Takara, Japan**), 1 µl of each primer of 20 pmol concentrations, 4.5 µl of water, and 6 µl of DNA template. The reaction was performed in an applied biosystem 2720 thermal cycler.

### Analysis of the PCR Products

The products of PCR were separated by electrophoresis on 1.5% agarose gel (Applichem, Germany, GmbH) in 1x TBE buffer at room temperature using gradients of 5V/cm. For gel analysis, 20 µl of the uniplex PCR products were loaded in each gel slot. Gelpilot 100 bp DNA Ladder (Qiagen, Germany, GmbH) was used to determine the fragment sizes. The gel was photographed by a gel documentation system (Alpha Innotech, Biometra) and the data was analyzed through computer software.

### Bacteriological examination and Serological Identification

Out of 120 examined fecal swabs obtained from the diarrheic dogs were subjected to bacteriological examinations, 68 isolates of *E.coli* were recovered in percentage of (56.6%). Serogrouping of (68) isolates of *E.coli* recovered from diarrheic dogs revealed 7 different "O" serogroups and 20 strains were untyped as illustrated in table ( 2 ).

### Antibiogram pattern

By comparing antibiotic susceptibility test results, the majority of the test isolates of *E.coli* serogroups were resistant to Oxytetracyclin, Ampicillin, Sulphamethazol and Cephalothin. However, some strains were susceptible to Cefotaxime, Ceftazidime, Imipenem and Cefepime (Table. 3).



**Table 1:** Primers sequences, target genes, amplicon sizes and cycling conditions.

Target gene	Primers sequences	Amplified segment (bp)	Primary denaturation	Amplification (35 cycles)			Final extension	Reference
				Secondary denaturation	Annealing	Extension		
<i>tetA(A)</i>	GGTCACTCGAACGACGTCA	576	94°C	94°C	50°C	72°C	72°C	22
	CTGTCCGACAAGTTGCATGA		5 min.	30 sec.	40 sec.	45 sec.	10 min.	
<i>Sul1</i>	CGG CGT GGG CTA CCT GAA CG	433	94°C	94°C	60°C	72°C	72°C	23
	GCC GAT CGC GTG AAG TTC CG		5 min.	30 sec.	45 sec.	45 sec.	10 min.	
<i>bla<sub>TEM</sub></i>	ATCAGCAATAAACCCAGC	516	94°C	94°C	54°C	72°C	72°C	24
	CCCCGAAGAACGTTTTTC		5 min.	30 sec.	40 sec.	45 sec.	10 min.	
<i>bla<sub>CTX</sub></i>	ATG TGC AGY ACC AGT AAR GTK ATG GC	593	94°C	94°C	45°C	72°C	72°C	25
	TGG GTR AAR TAR GTS ACC AGA AYC AGC GG		5 min.	30 sec.	45 sec.	45 sec.	10 min.	
<i>eaeA</i>	ATG CTT AGT GCT GGT TTA GG	248	94°C	94°C	55°C	72°C	72°C	26
	GCC TTC ATC ATT TCG CTT TC		5 min.	30 sec.	40 sec.	45 sec.	10 min.	
<i>Stx1</i>	ACACTGGATGATCTCAGTGG	614	94°C	94°C	58°C	72°C	72°C	27
	CTGAATCCCCCTCCATTATG							
<i>Stx2</i>	CCATGACAACGGACAGCAGTT	779	5 min.	30 sec.	45 sec.	45 sec.	10 min.	
	CCTGTCAACTGAGCAGCACTTTG							

**RESULTS**


**Table 2:** Serological identification of pathogenic strain of *E.coli* from diarrheic dogs.

<i>E.coli</i> Strains	No	%*
O <sub>157</sub>	4	5.85
O <sub>1</sub>	7	10.29
O <sub>44</sub>	3	4.41
O <sub>128</sub>	8	11.76
O <sub>26</sub>	10	14.70
O <sub>146</sub>	11	16.17
O <sub>55</sub>	7	10.29
Untyped	20	29.41
<b>Total</b>	<b>68</b>	<b>100</b>

\*The percentage % calculated according to total number of isolated strains of *E.coli* from diarrheic dogs

**Table 3:** Resistance pattern of *E.coli* pathogenic strains recovered from diarrheic dogs


<i>E.Coli</i> Strains	O <sub>157</sub>		O <sub>1</sub>		O <sub>44</sub>		O <sub>128</sub>		O <sub>26</sub>		O <sub>146</sub>		O <sub>55</sub>	
	(4)		(7)		(3)		(8)		(10)		(11)		(7)	
	R		R		R		R		R		R		R	
Chemotherapeutic agent	No	%	No	%	No	%	No	%	No	%	No	%	No	%
Ampicillin	2	50	3	60	3	100	6	75	6	60	11	100	4	57.14
Cefepime	1	25	3	60	2	66.66	5	62.5	5	50	7	63.63	1	14.28
Cephalothin	2	50	3	60	2	66.66	7	86.25	7	70	9	81.81	4	57.14
Cefpodoxime	3	75	2	80	1	33.33	3	37.5	4	40	4	36.36	2	28.57
Ceftriaxone	2	50	3	60	2	66.66	4	50	6	60	8	72.72	3	42.85
Cefotaxime	2	50	3	60	2	66.66	5	62.5	7	70	8	72.72	3	42.85
Ceftazidime	1	25	2	40	1	33.337	4	50	5	50	7	63.63	2	28.57
Imipenem	1	25	4	80	2	66.66	5	62.5	6	60	9	81.81	2	28.57
Oxytetracyclin	2	50	5	100	3	100	3	37.50	9	90	10	90.90	7	100
Sulphamethazol	4	100	4	100	3	100	8	100	8	80	5	45.45	3	42.85



**Figure 1:** L. Pulsed gel electrophoresis for detection of *sul 1* from different serogroups of *E.coli* were present in serogroups O<sub>157</sub>, O<sub>1</sub>, O<sub>44</sub>, O<sub>128</sub>, O<sub>26</sub> at 433bp. R. Pulsed gel electrophoreses for detection of *tet (A)* were present in serogroups O<sub>44</sub>, O<sub>26</sub>, O<sub>146</sub> and O<sub>55</sub> at 576bp.

**Table 4:** Molecular analysis of ESBL gene and virulence gene including *SXT1* , *SXT2* and *eaeA* gene.

Sample	Results						
	<i>eaeA</i>	<i>Stx1</i>	<i>Stx2</i>	<i>Sul1</i>	<i>TetA(A)</i>	<i>blaTEM</i>	<i>blaCTX</i>
1 (O <sub>157</sub> )	-	-	-	+	-	-	-
2(O <sub>1</sub> )	-	-	-	+	-	+	-
3(O <sub>44</sub> )	+	-	-	+	+	-	+
4(O <sub>128</sub> )	-	-	-	+	-	+	+
5(O <sub>26</sub> )	-	-	-	+	+	+	-
6(O <sub>146</sub> )	-	-	-	-	+	+	-
7(O <sub>55</sub> )	+	-	+	-	+	-	-

**Figure 2:** L. Pulsed gel electrophoresis for detection of bla TEM in different serogroups of *E.coli* were present in serogroups O<sub>1</sub>, O<sub>128</sub>, O<sub>26</sub> and O<sub>146</sub>. R. Pulsed gel electrophoreses for detection of bla CTX were present in serogroups O<sub>44</sub> and O<sub>128</sub>

## DISCUSSION

*Colibacillosis* is the major cause of morbidity and mortality and is responsible for significant economic losses worldwide<sup>28</sup>. Some serogroups of *E.coli* are known to play an important role as etiological agents of various diseases in dogs and cats, it was found to be associated with different diseases as diarrhea and urinary tract infection (UTI).

Also, Shiga toxin-producing *E.coli* (STEC) is responsible for a range of human gastrointestinal disease, including watery and/ or bloody diarrhea.

In this study, 68 *E.coli* strains were isolated from diarrheic dogs and the incidence rate was 56.6%. These results nearly lower than those reported<sup>29</sup> when 92 *E.coli* isolates from 35 diarrheic dogs. Ten isolates were characterized as extraintestinal pathogenic *E.coli* (EXPEC) strains<sup>4</sup> that isolated *E.coli* from diseased dogs in percentage of (31.3%) from fecal samples of dogs and owners.

In serological identification of isolated strains of *E.coli* revealed that 7 different "O" serogroups O<sub>157</sub>, O<sub>1</sub>, O<sub>44</sub>, O<sub>128</sub>, O<sub>26</sub>, O<sub>146</sub> and O<sub>55</sub> and (20) strains were untyped as shown in table (2). In our results do contrast in part with the author who they did serogrouping of *E.coli* from canine feces and reported the serogroups of O<sub>1</sub>, O<sub>2</sub>, O<sub>4</sub>, O<sub>7</sub>, O<sub>8</sub>, O<sub>16</sub>, O<sub>18</sub>, O<sub>25</sub> and O<sub>75</sub><sup>30</sup>.

Although antimicrobial therapy is an important tool for the treatment of the infection, resistance to antimicrobials is widespread and constitutes a great

concern in veterinary medicine. Indeed a close relationship between the use of antimicrobial agents for the treatment of infection in animals and level of observed resistance was exists<sup>14</sup>.

Table (3) illustrated that the antibiogram pattern of the isolated pathogens from diarrheic dogs. Multi-resistant against several antibiotics are recorded including Oxytetracyclines, Ampicillin, Sulphamethazol, Cephalothin and Impenem while variable results were recorded with the remaining tested chemotherapeutic agents. Dogs have therefore to be considering as an important reservoir for zoonotic *E.coli* strains, thus serving as substantial non-point source especially of strains capable of causing extra-intestinal diseases.

These result nearly conceded with those reported by many authors<sup>31,29</sup>, who isolated *E.coli* from dogs and reported that these strains were resistance to Streptomycin, Nalidixic acid, Tetracycline, Cephalothine and Amoxicillin was most frequently observed also by another author, in the resistant pattern, determined MDR of *E.coli* using Streptomycin, Amoxicillin, Ciprofloxacin, Ceftriaxone, Amoxicillin, Clavulanic<sup>32</sup>.

Cefotaxime resistant (CTX<sup>R</sup>) *E.coli* strains were isolated from fecal samples of healthy dogs in Mexico in percentage of (17%). Isolates that are resistant to 3<sup>rd</sup> generation cephalosporins and ciprofloxacin are becoming more common in health care facilities and the general Multidrug-resistant (MDR) *E.coli* has a similar role in opportunistic infection in dogs<sup>31</sup>. Recently there has been an increased frequency of infections in veterinary

setting, possible because of greater use of intensive care facilities newer generation antimicrobials and longer hospitalization period<sup>34</sup>.

Antimicrobial treatment selects for resistance in both pathogenic and commensal *Enterobacteriaceae*, and is considered the most important risk factor for acquiring extra intestinal infection with MDR strains<sup>35</sup>.

Table (4), figure (1), (2) showed the results from our study suggest that tested strains of *E.coli* producing Sul1 are belonged under serogroups O<sub>157</sub>, O<sub>1</sub>, O<sub>44</sub>, O<sub>128</sub> and O<sub>26</sub> at 433bp. Also serogroups O<sub>55</sub>, O<sub>146</sub>, O<sub>26</sub>, and O<sub>44</sub> were producing tet (A) at 576 bp., While serogroups O<sub>1</sub>, O<sub>128</sub>, O<sub>26</sub> and O<sub>146</sub> were producing blaTEM gene at 516 bp. Meanwhile serogroups O<sub>44</sub> and O<sub>128</sub> producing bla CTX at 503 bp.

These results are similar to another study by Carvalho et al., and they reported that 28.5% of the *E.coli* isolates from dogs were resistant to at least one antibiotic belonging to the third or fourth generation of Cephalosporins and were positive for ESBL by disk-approximation test<sup>4</sup>. They reported that *beta*-lactamase resistance strains having both (bla TEM and bla CTX) genes from human and dog origin together. Additionally, they reported that in dog isolates, the blaTEM gene was present in 66.7% of the strains that tested positive for ESBL genes. The bla CTX-M gene was detected in 75% of these isolates, they mentioned that, in human strains the prevalent ESBL gene family was the bla TEM family. The bla CTX-M was present in similar proportions in strains of human and dog origin from the same household.

The detection of ESBL gene in isolates of pet dogs was published in 1988; other studies have also reported the presence of the bla genes in isolates from dogs, especially isolates of clinical origin. The presence of clinically important bla TEM gene in dogs and clinical isolates have been reported since 2002<sup>36,37</sup>. However, the prevalence of these genes in dog is not well established so far.

In addition, *E.coli* (CTX<sup>R</sup>) Cefotaxime-resistant was recovered (17% of samples from healthy dogs and ESBL producing *E.coli* were detected 6% of samples). These samples carried the bla<sub>CTX-M-15</sub> gene and one isolate also carried the bla<sub>SHV-2</sub><sup>34</sup>.

While the *E.coli* gene *eaeA* express intimin, which is required for the production of attaching and effacing (AE) lesions in epithelial cells<sup>17</sup>. The *eaeA* genes were shown to be essential for intimate adherence and are present in most STEC strains included in Enterohaemorrhagic *E.coli* (EHEC) groups.

Our study revealed the presence of *eaeA* gene among serogroups O<sub>44</sub> and O<sub>55</sub> and PCR products of this gene at 248bp. (Table 4, picture 3), while *E.coli* isolates showed the presence *stx2* gene among serogroup O<sub>55</sub> only. None of the *E.coli* isolate examined by PCR showed that the presence of *stx1*.

These findings are similar with Kaper et al., and they stated that the major virulence factor and a defining characteristic of STEC is *stx*<sup>17</sup>. These potent cytotoxins not only inhibit protein synthesis in cells, but also induce the lytic characteristic of programmed cell death (apoptosis), while another author mentioned that no STEC strains were identified among the *E.coli* isolates from feces or urine<sup>38</sup>.

The strains which carry only *stx2* are more virulent than those carry only *stx1* or even both *stx1* and *stx2* and more associated with cases of HUS in Humans<sup>39,40</sup>. The presence of *eaeA* gene in STEC strains have been strongly correlated to their implication in severe illness resulting HUS<sup>41</sup>. While STEC strains lacking *eaeA* gene have been reported to cause outbreaks<sup>42</sup>. Attaching effacing *E.coli* (AEEC) presenting with AE lesions has been associated with diarrheal illness in dogs<sup>15</sup>, also AEEC strains resembling typical enteropathogenic *E.coli* (*eae+*) were isolated from cats in a small number (6.5%) of cases and pathogenic AEEC may transferred to humans by direct contact between animals and humans<sup>43</sup>.

## CONCLUSION AND RECOMMENDATIONS

In conclusion, *E.coli* one of most causes of diarrhea in dogs cross infection may occurred to human so diarrheic dogs must be well diagnosed and must be apply sensitivity test against isolated pathogens to correct treatment and prevent the transmission of multidrug resistant gene (MDR). Presence of virulence genes in *E.coli* from the pet animal are become serious public health concern. Because of possible transfer of these antibiotic resistant strains between companion animals and humans. Future studies are necessary to focus on risk factor for transmission of  $\beta$ -lactamase producing *E. coli* between pets and humans in household environment.

## REFERENCES

1. Usein CR, Chitoiu DT, Ciontea S, Condei M and Damian M, *E.coli* pathotypes associated with diarrhea in Romanian children younger than 5 years of age, Jpn J Infect Dis, 62 (4), 2009, 289-293.
2. Croxen MA and Finlay BB, Molecular mechanisms of *Escherichia coli* pathogenicity, Nature Reviews Microbiology, 8 (1), 2010, 26–38.
3. Kaper JB, Molecular pathogenesis of Enteropathogenic *E.coli*, Molecular Genetics of Bacterial Pathogenesis, 1<sup>st</sup> Ed. Asm, Washington, Du, U SA, 2004, 1-2
4. Carvalho AC, Barbosa AV, Arais LR, Ribeiro PF, Carneiro VC and Cerqueira, AMF, Resistance patterns, ESBL genes, and genetic relatedness of *Escherichia coli* from dogs and owners, Braz J Microbiol, 47(1), 2016, 150-158.
5. Ben Sallem R, Ben Slama K, Saenz Y, Rojo-Bezales B, Estepa V, Jouini A, Gharsa, H, Klibi N, Boudabous A and Torres C, Prevalence and characterization of extended-spectrum  $\beta$ -lactamase (ESBL)- and CMY-2-producing *Escherichia coli* isolates from healthy food-producing animals in Tunisia, Foodborne Pathog Dis, 9(12), 2012, 1137–1142.



6. Albrechtova K, Kubelova M, Mazancova J, Dolejska M, Literak I and Cizek A, High prevalence and variability of CTX-M-15-producing and fluoroquinolone resistant *Escherichia coli* observed in stray dogs in rural Angola, *Microb Drug Resist*, 20(4), 2014, 372-375.
7. Cantón R1, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM, Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe, *Clin Microbiol Infect*, (14) 1, 2008, 144-53.
8. Cortes P, Blanc V, Mora A, Dahbi G, Blanco JE, Blanco M, Lopez C, Andreu A, Navarro F, Alonso MP, Isolation and characterization of potentially pathogenic antimicrobial-resistant *Escherichia coli* strains from chicken and pig farms in Spain, *Appl Environ Microbiol*, 76(9), 2010, 2799-2805.
9. Hordijk J, Schoormans A, Kwakernaak M, Duim B, Broens E, Dierikx C, Mevius D, Wagenaar JA. High prevalence of fecal carriage of extended spectrum  $\beta$ -lactamase/AmpC-producing Enterobacteriaceae in cats and dogs, *Front Microbiol.*, 4, 2013, 1–5.
10. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, Fruth A, Beutlich J, Guerra B, Wieler LH, Guenther S, Emergence of human pandemic O25:H4- ST131 CTX-M-15 extended-spectrum- $\beta$ -lactamase-producing *Escherichia coli* among companion animals, *J Antimicrob Chemother*, 65(4), 2010, 651–660.
11. Sallem RB, Gharsa H, Slama KB, Rojo-Bezares B, Estepa V, Porres-Osante N, Jouini, A, Klibi N, Saenz Y, Boudabous A, Torres C, First detection of CTX-M-1, CMY-2, and QnrB19 resistance mechanisms in fecal *Escherichia coli* isolates from healthy pets in Tunisia, *Vector-Borne and Zoonotic Diseases*, 13(2), 2013, 98–102.
12. Bortolaia V, Hansen KH, Nielsen CA, Fritsche TR and Guardabassi L, High diversity of plasmids harbouring blaCMY-2 among clinical *Escherichia coli* isolates from humans and companion animals in the upper Midwestern USA, *J Antimicrob Chemother*, 69(6), 2014, 1492–1496.
13. Karlowsky JA, Jones M.E, Thornsberry C, Friedland IR and Sahm DF, Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998-2001, *Antimicrob. Agents Chemother*, 47(5), 2003, 1672–1680.
14. Carattoli A, Resistance plasmid families in Enterobacteriaceae, *Antimicrob. Agents Chemother*, 53(3), 2009, 2227-2238.
15. Beutin L, *Escherichia coli* as a pathogen in dogs and cats, *Vet. Res*, 30(2), 1999, 285- 298.
16. Bentancor A, Rumi MV and Gentilini MV, Shiga toxin-producing and attaching and effacing *Escherichia coli* in cats and dogs in a high hemolytic uremic syndrome incidence region in Argentina, *FEMS Microbiol Lett*, 267(2), 2007, 251-256.
17. Kaper JB, Nataro JP and Mobley HT, Pathogenic *Escherichia coli*, *Nat Rev Microbiol*, 2(2), 2004, 123-140.
18. Koneman EW, Allen SDJ, Schrecken BPC and Winn WC, the Enterobacteriaceae. In: *Color Atlas and Textbook of Diagnostic Microbiology*. 5<sup>th</sup> Ed, JB Lippincott Co, Philadelphia, 1997, 171-239.
19. Ewing WH, Edward's and Ewing's, Identification of Enterobacteriaceae 4<sup>th</sup> Ed. Elsevier Science New York, 1986.
20. Quinn PJ, Carter ME, Markey Bk, Donnelly WJC and Leonard FC, *Veterinary Microbiology and Microbial Disease*, Great Britain by MPG, Book Ltd, Bodmin, Cornwall, U.K. 1986 .
21. EUCAST, The European committee on Antimicrobial susceptibility testing, European Society of clinical microbiology and infectious diseases Breakpoint tables for interpretation of MICs and Zone diameter Version 6, 2016
22. Randall LP, Cooles SW, Osborn MK, Piddock LJV and Woodward MJ, Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of *Salmonella enterica* isolated from humans and animals in the UK, *J Antimicrob Chemother*, 53(2), 2004, 208–216.
23. Ibekwe AM, Murinda SE. and Graves A.K, Genetic Diversity and Antimicrobial Resistance of *Escherichia coli* from Human and Animal Sources Uncovers Multiple Resistances from Human Sources. *PLoS ONE*, 6 (6) , 2011, e20819.
24. Colom K, Pèrez J, Alonso R, Fernández-Aranguiz A, Lariño E and Cisterna R , Simple and reliable multiplex PCR assay for detection of blaTEM, bla(SHV) and blaOXA-1 genes in Enterobacteriaceae. *FEMS Microbiology Lett*, 223(2), 2003, 147-151
25. Archambault M, Petrov P, Hendriksen RS, Asseva G, Bangtrakulnonth A, Hasman H and Aarestrup FM, Molecular characterization and occurrence of extended-spectrum beta-lactamase resistance genes among *Salmonella enterica* serovar Corvallis from Thailand, Bulgaria, and Denmark, *Microb Drug Resist*, 12(3), 2006, 192-8.
26. Bisi-Johnson MA, Obi CL, Vasaikar S.D, Baba KA and Hattori T, Molecular basis of virulence in clinical isolates of *Escherichia coli* and *Salmonella species* from a tertiary hospital in the Eastern Cape, South Africa. *Gut Pathog*, 3, 2011: 1-8
27. Dipineto L, Santaniello A, Fontanella M, Lagos K, Fioretti A and Menna LF, Presence of Shiga toxin-producing *Escherichia coli* O157:H7 in living layer hens, *Lett Appl Microbiol*, 43(3), 2006, 293-295.
28. Schouler C, Schaeffer B, Brée A, Mora A, Dahbi G, Biet F, Oswald E, Mainil J, Blanco J, and Moulin-Schouleur M, Diagnostic Strategy for Identifying Avian Pathogenic *Escherichia coli* Based on Four Patterns of Virulence Genes, *J Clin Microbiol*, 50(5), 2012, 1673–1678.
29. Paula DCJS and Marin, JM, Isolation of extraintestinal pathogenic *Escherichia coli* from diarrheic dogs and their antimicrobial resistance profile. *Braz J Microbiol* 39(3), 2008, 498-500.
30. Johnson JR, Stell AL and Dalavari D, Canine Feces as a Reservoir of Extraintestinal Pathogenic *Escherichia coli*. *Infect Immun.*, 69(3), 2001, 1306–1314.
31. Paterson DL, Resistance in Gram-negative bacteria: Enterobacteriaceae, *Am J Med*, 119(6), 2006, S20-S28.
32. Luaibi OK, Isolation of *Escherichia coli* from young lions, dogs and sheep with determination of antibiotic resistance, *JPCS*, 7, 2013, 19-21.
33. Rocha-Gracia RC, Cortés-Cortés G, Lozano-Zarain P, Bello F, Martínez-Laguna Y and Torres C, Faecal *Escherichia coli*



- isolates from healthy dogs harbour CTX-M-15 and CMY-2  $\beta$ -lactamases, *Vet J*, 203(3), 2015, 315-319.
34. Ogeer-Gyles JS, Mathews KA and Boerlin P, Nosocomial infections and antimicrobial resistance in critical care medicine, *J Vet Emerg Crit Care*, 2006,16-18.
35. Van den Bogaard A.E and Stobberingh EE, Epidemiology of resistance to antibiotics. Links between animals and humans, *Int J Antimicrob Agents*,14(4), 2000, 327-335.
36. Griffin PMD, *Escherichia coli* O157:H7 and other enterohemorrhagic *Escherichia coli*, in: Blaser M.J., Ravdin J.L, Greenberg H.B., Guerrant R.L. (Eds.), *Infections of the Gastrointestinal Tract*. Raven Press, New York, 1995, 739-761.
37. Cherifi A, Contrepolis M, Picard B., Goullé P, Orskov 1, Orskov F, De Rycke J, Clonal relationships among *Escherichia coli* serogroup O6 isolates from human and animal infections, *FEMS. Microbiol Lett.* 64(2-3), 1991, 225-230.
38. Caliman MW and Marin JM, Virulence genes in *Escherichia coli* isolated from feces and urine of cats, *Arq Bras Med Vet Zootec*, 66(4), 2014, 1287-1290.
39. Lee GY, Jang HI, Hwang IG and Rhee MS, Prevalence and classification of pathogenic *Escherichia coli* isolated from fresh poultry and pork in Korea, *Int J food Microbiol*,134(3),2009,196-200.
40. Mohammed MA, Sallam KI, Eldaly EAZ, Ahdy AM and Tamura T, Occurrence, serotypes and virulence genes of non-O157 Shiga toxin-producing *Escherichia coli* in fresh beef, ground beef, and beef burger, *Food Control*, 37, 2014, 182-187.
41. Ojo OE, Ajuwape AT, Otesile EB, Owoade AA, Oyekunle MA and Adetosoye AI, Potentially zoonotic shiga toxin-producing *Escherichia coli* serogroups in the faeces and meat of food-producing animals in Ibadan", *Int J Food Microbiol*, 142 (1-2), 2010, 214-221.
42. Paton JC and Paton AW, Pathogenesis and diagnosis of Shiga toxin-producing *Escherichia coli* infections, *Clin microbiol rev*, 11(3), 1998, 450-479.
43. Krause G, Zimmermann S and Beutin L, Investigation of domestic animals and pets as a reservoir for *Escherichia coli* types, *Vet. Microbiol*, 106 (1-2), 2005, 87-95.

**Source of Support:** Nil, **Conflict of Interest:** None.

